News

The study will examine women’s blood for a number of cancer related biomarkers, which are specific proteins having concentrations that are measurably different in patients with breast cancer.

Previously referred to as DepoMorphine, DepoDur is a novel single dose sustained-release injectable formulation of morphine designed for the control of pain after major surgery. SkyePharma expects that

The positive opinion is for Sutent (sunitinib malate) in metastatic renal cell carcinoma (mRCC) after failure of interferon alpha or interleukin-2-based therapy. The positive opinion was also granted

The positive opinion is for Tysabri (natalizumab) as a treatment for relapsing-remitting multiple sclerosis (MS) to delay the progression of disability and reduce the frequency of relapses. The

Tapentadol (CG5503/ R331333) is a novel, centrally acting analgesic with a dual mechanism of action developed by German pharmaceutical company Grunenthal. Ortho-McNeil Pharmaceutical entered into a licensing agreement

The European Commission decision regarding marketing authorization for Kaletra (lopinavir/ritonavir) is expected within 90 days. The anticipated marketing authorization from the European Commission also will enable Abbott to

The randomized, open-label trial tested the clinical potential of the drug in patients with stage IIIB and IV non-small cell lung cancer (NSCLC). The analysis confirms a median

The positive opinion is based on results from a phase III clinical trial named ATLAS. In October 2005, Abbott submitted a supplemental biologics license application (sBLA) with the

Importantly, the shorter 24-week regimen was also associated with a low rate of relapse – only 6% in genotype 2 patients and 10% in genotype 3 patients, which